Overview

Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C

Status:
Unknown status

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

The objective is to assess the efficacy, dosing, safety and tolerance of Y- shaped pegylated interferon (YPEG-IFNα-2a) plus ribavirin in Egyptian patients with chronic hepatitis C and with no prior treatment for hepatitis C virus (HCV). Methods: Randomized, Open-label trial, in 3 parallel groups (each of 100 patients)

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

BioGeneric Pharma

Collaborator:

Xiamen Amoytop Biotech Co., Ltd.

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin